Aimmune Therapeutics, Inc. (NASDAQ:AIMT) currently has an Average Broker Rating of 1. This number is based on the 4 sell-side firms polled by Zacks. The ABR rank within the industry stands at 13.
Investors are frequently on the search for the secret to creating that winning portfolio. Many individual investors would agree that information is highly important when picking stocks. Possessing the correct information about a public company is of the utmost importance. Knowing how to interpret the information is another skill investors may need to master before becoming fully immersed in the stock market. Taking the time to properly examine a company before purchasing shares may be the difference between healthy profits and disappointing losses. If a company looks good after the research is complete, patience may still be desirable. Often times, a good stock will continue to be good in the future. Dealing with market volatility is normal, but exploring all aspects of a company may be a good way to combat day to day volatility.
Analysts on a consensus basis are expecting that the stock will reach $37 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry or sector of the economy. They exert considerable influence in today’s marketplace. Analysts’ recommendations or reports can influence the price of a company’s stock—especially when the recommendations are widely disseminated through television appearances or through other electronic and print media. The mere mention of a company by a popular analyst can temporarily cause its stock to rise or fall—even when nothing about the company’s prospects or fundamentals has recently changed.
Analysts often use a variety of terms—buy, strong buy, near-term or long-term accumulate, near-term or long-term over-perform or under-perform, neutral, hold—to describe their recommendations. But the meanings of these terms can differ from firm to firm. Rather than make assumptions, investors should carefully read the definitions of all ratings used in each research report. They should also consider the firm’s disclosures regarding what percentage of all ratings fall into either “buy,” “hold/neutral,” and “sell” categories.
Research analysts are predicting that Aimmune Therapeutics, Inc. (NASDAQ:AIMT) will report earnings of $-0.71 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Most recently Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted quarterly earnings of $-0.52 which compared to the sell-side estimates of -0.64. The stock’s 12-month trailing earnings per share stands at $-2.03. Shares have moved $17.08 over the past month and more recently, $-1.33 over the past week heading into the earnings announcement. There are 2 analyst projections that were taken into consideration from respected brokerage firms.
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) closed the last session at $20.77 and sees an average of 361012.84 shares trade hands in each session. The 52-week low of the stock stands at $10.26 while the current level stands at 63.93% of the 52-week High-Low range. Looking further out we can see that the stock has moved 6.13% over the past 12 weeks and 1.56% year to date.
4 analysts rate Aimmune Therapeutics, Inc. a Buy or Strong Buy, which is 100% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.
Typically bull markets are times when investors may be willing to be a bit more speculative with stock selection. Managing risk is generally at the forefront of many strategies. Investors trying to shift the odds in their favor may be searching for the perfect balance and diversification to help mitigate the risk and enjoy healthier profits. With so many different stocks to choose from, it may take a while to zoom in or a particular set. Investors will also be watching the next wave of economic data to get a better sense of how the overall economy is fairing. With so much noise in the markets, it may be necessary to narrow the gaze in order to set the table for success. Investors may be on the lookout for the major catalyst that either keeps the bulls charging into the second half the year, or wakes up the sleeping bears.